Edition:
United Kingdom

Xenon Pharmaceuticals Inc (XENE.OQ)

XENE.OQ on NASDAQ Stock Exchange Global Market

10.55USD
13 Jul 2018
Change (% chg)

$0.90 (+9.33%)
Prev Close
$9.65
Open
$9.70
Day's High
$10.60
Day's Low
$9.70
Volume
32,513
Avg. Vol
23,514
52-wk High
$11.00
52-wk Low
$2.15

Latest Key Developments (Source: Significant Developments)

Xenon Pharmaceuticals Announces At-The-Market Equity Offering
Thursday, 12 Jul 2018 

July 12 (Reuters) - Xenon Pharmaceuticals Inc ::XENON PHARMACEUTICALS ANNOUNCES AT-THE-MARKET EQUITY OFFERING.XENON PHARMACEUTICALS INC SAYS ENTERED INTO AN AT--MARKET EQUITY OFFERING SALES AGREEMENT WITH JEFFERIES AND STIFEL, EFFECTIVE AS OF JULY 11, 2018.XENON PHARMACEUTICALS INC SAYS UNDER AT--MARKET EQUITY OFFERING SALES AGREEMENT, CO MAY SELL COMMON SHARES FOR UP TO $50.0 MILLION.  Full Article

Xenon Pharmaceuticals Entered At-The-Market Equity Offering Sales Agreement To Sell Shares Having Sales Proceeds Of Up To $50 Mln
Thursday, 12 Jul 2018 

July 12 (Reuters) - Xenon Pharmaceuticals Inc ::XENON PHARMACEUTICALS SAYS ON JULY 11, ENTERED INTO AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT TO SELL SHARES HAVING SALES PROCEEDS OF UP TO $50 MILLION.  Full Article

Xenon Pharmaceuticals Expects To Have Ongoing XEN1101 Phase 1 Clinical Trial Completed By Mid-Year
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Xenon Pharmaceuticals Inc ::XENON PHARMACEUTICALS OUTLINES KEY MILESTONES FOR 2018.XENON PHARMACEUTICALS INC - EXPECT TO HAVE ONGOING XEN1101 PHASE 1 CLINICAL TRIAL COMPLETED BY MID-YEAR.XENON PHARMACEUTICALS INC - IN SECOND HALF OF THIS YEAR, ANTICIPATE HAVING COMPLETED XEN901 PHASE 1 CLINICAL TRIAL.XENON PHARMACEUTICALS INC - ANTICIPATE THAT BOTH XEN1101 AND XEN901 COULD BE IN PHASE 2 DEVELOPMENT BY END OF THIS YEAR.XENON PHARMACEUTICALS INC - AS OF DECEMBER 31, 2017, CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $43.7 MILLION.XENON PHARMACEUTICALS INC - BASED ON CURRENT ASSUMPTIONS, XENON ANTICIPATES HAVING SUFFICIENT CASH TO FUND OPERATIONS INTO MID-2019.  Full Article

Xenon Pharma Says Entered Into Loan And Security Agreement With Silicon Valley Bank
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Xenon Pharmaceuticals Inc ::XENON PHARMACEUTICALS- ON DEC 18, CO, UNIT ENTERED INTO LOAN AND SECURITY AGREEMENT WITH SILICON VALLEY BANK - SEC FILING.XENON PHARMACEUTICALS - PURSUANT TO AGREEMENT, BANK AGREED TO EXTEND TERM LOANS TO CO WITH AGGREGATE PRINCIPAL AMOUNT OF UP TO $15 MILLION.XENON PHARMACEUTICALS INC - BORROWINGS UNDER LOAN AGREEMENT WILL CONSIST OF UP TO THREE SEPARATE TRANCHES.  Full Article

Xenon Pharmaceuticals reports Q3 loss per share $0.43
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Xenon Pharmaceuticals Inc :Xenon Pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 revenue $300,000 versus $400,000.Xenon Pharmaceuticals Inc - qtrly loss per share $0.43.  Full Article

Xenon Pharma announces initiation of XEN1101 phase 1 clinical trial
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Xenon Pharmaceuticals Inc :Xenon Pharmaceuticals announces initiation of XEN1101 phase 1 clinical trial.XEN1101 phase 2 proof-of-concept clinical trial anticipated to begin in Q3 2018​.Expect to file an IND equivalent application in Q4 of this year for XEN901​.  Full Article

Xenon Pharmaceuticals reports Q2 revenue $400,000 versus $4.0 million
Wednesday, 3 Aug 2016 

Xenon Pharmaceuticals Inc : Xenon pharmaceuticals reports second quarter 2016 financial results and provides corporate update .Q2 revenue $400,000 versus $4.0 million.  Full Article

BRIEF-Xenon Pharmaceuticals Q1 Net Loss Per Common Share $0.21

* XENON PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE